Herantis Pharma Plc.

Licentia, Ltd.

Herantis Pharma Oyj

Hermo Pharma Ltd.

Raimo Tuominen

Mart Saarma

Juha Lauren

Tonis Timmusk

Päivi Lindholm

Maria Lindahl

Merja Voutilainen

Johan Peränen

Mikko Airavaara

Veli-Matti Leppänen

Jaan-Olle Andressoo

Päivi Pulkkila

Paeivi Lindholm

Johan Peranen

Veli-Matti Leppanen

The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.

Neurotrophic factor MANF and uses thereof

The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.

MANF2 for treatment of Parkinson's disease

A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.

Treatment with a pharmaceutical composition comprising MANF2 necleic acid

Neurotrophic factor protein and uses thereof

Growing community of inventors

Vantaa, Finland

Raimo Tuominen